Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Marketable securities - available-for-sale debt securities (Tables)

Marketable securities - available-for-sale debt securities (Tables)

9 Months Ended

Sep. 30, 2024

As of September 30, 2024, the Company had the following investments in marketable securities (in thousands):


				Gross		Gross		Aggregate
	Remaining	Amortized		unrealized		unrealized		estimated
	contractual maturity	cost		gains		losses		fair value
Cash equivalents:
U.S. Treasury securities	Less than 3 months	$	3,996	$	—	$	—	$	3,996
		$	3,996	$	—	$	—	$	3,996

Available-for-sale debt securities:
Agency bonds	Less than 3 months	$	10,072	$	9	$	—	$	10,081
Corporate debt securities	Less than 3 months		15,172		3		(1)		15,174
U.S. Treasury securities	Less than 3 months		18,867		13		—		18,880
Agency bonds	3 months to 1 year		6,926		9		—		6,935
Corporate debt securities	3 months to 1 year		1,994		3		—		1,997
U.S. Treasury securities	3 months to 1 year		16,262		20		—		16,282
		$	69,293	$	57	$	(1)	$	69,349

Schedule of aggregate fair value and number of securities held by the Company in an unrealized loss position

The aggregate fair value (in thousands) and number of securities held by the Company (including those classified as cash equivalents) in an unrealized loss position as of September 30, 2024 and December 31, 2023 are as follows:



	September 30, 2024						December 31, 2023
	Fair market value of investments in an unrealized loss position		Number of investments in an unrealized loss position		Unrealized losses		Fair market value of investments in an unrealized loss position		Number of investments in an unrealized loss position		Unrealized losses
Marketable securities in a continuous loss position for less than 12 months:
Corporate debt securities	$	1,481		1	$	—	$	1,600		1	$	(1)
	$	1,481		1	$	—	$	1,600		1	$	(1)